Accentia Biopharmaceuticals Complies with Nasdaq Marketplace Rule 4350(b)(1)(B)

Lead Author: [none given]

Business Wire. New York: , 2008-01-04

Accentia Biopharmaceuticals, Inc., Tampa

Douglas Calder, Director of Investor Relations & Public

Relations, 813-864-2554, ext.258

dwcalder@accentia.net

or

Susan Bonitz, Ph.D., Director, Program Coordination

813-864-2554, ext.277

sbonitz@accentia.net

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), in compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion that contains a going concern qualification, disclosed that its Annual Report (Form 10-K) for the fiscal year ended September 30, 2007 contains a going concern qualification from its independent registered public accounting firm, Aidman, Piser & Company, P.A. As in the past, Accentia continues to consolidate its financial statements with its majority-owned subsidiary, Biovest International, Inc., although it is not funding Biovest. This audit opinion is consistent with previous opinions included in the Company's 2005 and 2006 financial statements, which reflect the continued developmental stage of Accentia's consolidated business with Biovest.

This announcement does not represent any change or amendment to the Company's fiscal 2007 financial statements or to its Annual Report, filed on Form 10-K, with the SEC on December 28, 2007.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. The Company's lead product candidate is SinuNase(TM), a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune(TM), to treat numerous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. (OTCBB:BVTI) and a royalty interest in Biovest's lead drug candidate, BiovaxID(TM) and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business, which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry.

For further information, please visit http://www.Accentia.net.

MIB Abstract ID Number: 14343

Proquest Identifier: 1407894261

* To access this Proquest article the user must create an account.

Genentech begins NHL trial with SGN-40 triggering milestone payment to SG

Lead Author: [none given]

Pharma Agreement News, 2008-01-08

Seattle Genetics ' (SG) collaborator, Genentech , has initiated a Phase Ib trial of SGN-40 in combination with Rituxan (rituximab) for patients with relapsed follicular or marginal zone non-Hodgkin’s lymphoma (NHL). As a result, SG will receive a $4US million milestone payment from Genentech. The study will enrol patients with relapsed follicular or marginal zone NHL at multiple cancer centres in the US.

The trial is designed to assess the safety, pharmacokinetics and preliminary activity of escalating doses of SGN-40 when combined with rituximab. In collaboration with Genentech, SG is conducting a joint development plan for SGN-40 that includes six ongoing or planned clinical trials of SGN-40 both as a single agent and combined with standard therapies for NHL and multiple myeloma. A Phase IIb trial of SGN-40 in combination with R-ICE (Rituxan, ifosfamide, carboplatin and etoposide) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a Phase II single-agent trial in DLBCL and a Phase Ib study of SGN-40 in combination with Revlimid (lenalidomide) in relapsed or refractory multiple myeloma are ongoing. Under the terms of the collaboration agreement, SG received an up-front payment of $60US million in February 2007, and is entitled to receive potential milestone payments exceeding $800US million and escalating double-digit royalties starting in the mid-teens on sales of SGN-40.

MIB Abstract ID Number: 14362

*To access this Lexis-Nexis article the user must create an account.

Seattle Genetics to Present at the 26th Annual JPMorgan Healthcare Conference

Lead Author: [none given]

Business Wire. New York: , 2008-01-04

Seattle Genetics, Inc.

Corporate Communications

Peggy Pinkston, 425-527-4160

ppinkston@seagen.com

Logo: http://www.seattlegenetics.com

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will speak at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008, at 3:30 p.m. Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco, California. A live webcast of the presentation will be available from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section.

MIB Abstract ID Number: 14363

*To access this Lexis-Nexis article the user must create an account.

Reports from University of Illinois highlight recent research in monoclonal antibodies

Lead Author: [none given]

Drug Law Weekly, 2008-01-08, EXPANDED REPORTING; Pg. 951

In this recently published article, scientists in the United States conducted a study "To assess whether intravitreal rituximab 1 mg/0.1 cc penetrates the retina of Dutch-belted rabbits. Two right eyes of two rabbits were injected with intravitreal rituximab 1 mg/0.1 mL, and one right eye of one rabbit was injected with intravitreal tissue plasminogen activator (tPA) 12.5 mu g/0.1 mL, as a protein control."

"The three left eyes received no intravitreal injections. The rabbits were killed; the eyes were enucleated and immediately frozen at -80 degrees C. Rituximab was detected using rabbit antihuman IgG (whole molecule) peroxidase conjugated antibody. tPA was detected using an antihuman IgG with a sheep antilhuman tPA antibody conjugated with peroxidase. There was staining in all retinal layers of the two eyes injected with intravitreal rituximab, and no staining of the retina in the eye injected with intravitreal tPA. The three control eyes showed no staining in any retinal layer.," wrote J.S. Pulido and colleagues, University of Illinois.

The researchers concluded: "Intravitreal rituximab at a dose of 1 mg/0.1 cc penetrates the retina of Dutch-belted rabbits while the control intravitreal tPA at a dose of 12.5 mu g/0.1 cc does not."

Pulido and colleagues published their study in Retina - the Journal of Retinal and Vitreous Diseases (Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina - the Journal of Retinal and Vitreous Diseases, 2007;27(8):1071-1073).

For additional information, contact D. Shukla, University of Illinois, Dept. of Ophthalmology & Visual Science, 1855 W Taylor St. MC 648, Chicago, IL 60612, USA.

The publisher's contact information for the Retina - the Journal of Retinal and Vitreous Diseases is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.

MIB Abstract ID Number: 14361

*To access this Lexis-Nexis article the user must create an account.

Lymphoma; Study data from E. Domingodomenech and co-authors update knowledge of lymphoma

Lead Author: [none given]

Hematology Week. Atlanta:, 2008-01-07, pg. 189

2008 JAN 7 - (NewsRx.com) -- According to a study from Barcelona, Spain, "Background and Objectives Single-nucleotide polymorphisms (SNP) in interleukin-10 (IL-10) genes can influence immune responses, which may affect the outcome of patients with lymphoid neoplasms. The aim of this study was to explore the association between polymorphisms Of IL-10-(1082A >G) and IL-10-(3575T >A) with the overall survival in patients with lymphoid neoplasms."

"Design and Methods We analyzed two IL-10 SNP (-1082 and -3575) in 472 consecutive cases with lymphoid neoplasms. Genotypes were tested for association with overall survival and classical prognostic factors by multivariate analysis. Haplotype analysis was carried out using the haplostats package implemented in R software. The implications for survival of patients with lymphoma were evaluated using multivariate analysis. Results Lymphoma patients with the IL-10-(3575T >A) genotype had a better overall survival (p= 0.002), as did the subgroup with non-Hodgkin's lymphoma (NHL) (p=0.05). Patients with the IL10(1082GG) genotype had a better median overall survival (p=0.05). When both genotypes were included in a multivariate analysis, IL-10-(3575AA) genotype was the only independent prognostic factor for survival (HR=0.20, 95%Cl 0.05- 0.92). Patients with the IL-10-(1082A >G) and -3575 G-A/G-A diplotype had a longer overall survival (p=0.003) and this combination appeared to be an independent prognostic factor for survival (HR:0.26; 95%Cl 0.08-0.83). Interpretation and Conclusions The IL-10-(357BA/A) genotype was identified as a marker of favorable survival. Because the IL-10-(1082) and -3575 G-A/G-A diplotype was also identified as an indicator of longer survival, we cannot exclude the potential additive role of the IL-10-(1082GG) genotype," wrote E. Domingodomenech and colleagues.

The researchers concluded: "These results need to be replicated in larger series and examined in different NHL subtypes."

Domingodomenech and colleagues published the results of their research in Haematologica - the Hematology Journal (Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica - the Hematology Journal, 2007;92(11):1475-1481).

For additional information, contact E. Domingodomenech, Hospital Llobregat, Institute Catala Oncology, Dept. of Hematology, Avda Gran Via S-N, Km 2-7, Barcelona 08907, Spain.

The publisher of the Haematologica - the Hematology Journal can be contacted at: Ferrata Storti Foundation, Via Giuseppe Belli 4, 27100 Pavia, Italy.

MIB Abstract ID Number: 14340

Proquest Identifier: 1407185281

* To access this Proquest article the user must create an account.

Lymphoma; Study data from American University of Beirut, Department of Anesthesiology update understanding of lymphoma

Lead Author: [none given]

Stem Cell Week. Atlanta: , 2008-01-07, pg. 43

2008 JAN 7 - (NewsRx.com) -- Investigators publish new data in the report 'Value of pretransplant pulmonary function tests in predicting pulmonary complications after autologous peripheral stem cell transplantation.' According to recent research from Beirut, Lebanon, "The aim of this study was to evaluate the value of pulmonary function tests performed before an autologous peripheral stem cell transplant (APSCT) in identifying patients who are at risk for developing post-transplant pulmonary complications. This retrospective study included patients who underwent autologous peripheral stem cell transplantation from January 1997 to December 2006."

"The total sample consisted of 43 patients with 24 patients (55.8%) having multiple myeloma, 9 patients (20.9%) having Hodgkin's lymphoma, and 10 patients (23.3%) having non-Hodgkin's lymphoma. The patients' average age at the time of diagnosis and at the time of APSCT was 41.8 +-14.6 and 43.1 +-14.2 years, respectively. After APSCT, 8 patients (18.6%) had pulmonary complications all of which were infectious pneumonia. The mean pretransplant forced midexpiratory flow (FEF(25-75%)) in the patients who developed post- transplant pulmonary complications was significantly lower than the mean pretransplant FEF(25-75%) in the patients who did not develop post-transplant pulmonary complications (75.5 +-19.9% vs. 104.3 +- 24.5%, p=0.004). There were no other differences in the pretransplant pulmonary function test parameters between the patients who developed post-transplant pulmonary complications and the patients who did not develop post-transplant pulmonary complications," wrote M. El-Khatib and colleagues, American University of Beirut, Department of Anesthesiology.

The researchers concluded: "Our results showed that patients with decreased pretransplant FEF(25-75%) are at risk for developing pulmonary complications in the post autologous stem cell transplantation period."

El-Khatib and colleagues published their study in Lung (Value of pretransplant pulmonary function tests in predicting pulmonary complications after autologous peripheral stem cell transplantation. Lung, 2007;185(6):321-4).

For additional information, contact M. El-Khatib, American University of Beirut Medical Center, Dept. of Anesthesiology, Beirut, Lebanon.

Publisher contact information for the journal Lung is: Springer, 233 Spring Street, New York, NY 10013, USA.

MIB Abstract ID Number: 14341

Proquest Identifier: 1407225861

* To access this Proquest article the user must create an account.

Non-Hodgkin Lymphoma; Researchers from Kyungpook National University, Medical Department describe findings in non-hodgkin lymphoma

Lead Author: [none given]

Stem Cell Week. Atlanta:, 2008-01-07, pg. 25

2008 JAN 7 - (NewsRx.com) -- "The current study aimed to evaluate the efficacy and toxicity of a combination of intravenous busulfan, cyclophosphamide and etoposide (i.v. Bu/Cy/E) as a conditioning regimen prior to autologous hematopoietic stem cell transplantation in patients with non-Hodgkin's lymphoma (NHL)," researchers in South Korea report.

"Sixty-four patients with relapsed/ refractory (n = 36) or high- risk (n = 28) lymphoma were enrolled. The high-dose chemotherapy consisted of i.v. Bu (0.8 mg kg(-1) i.v. q 6h from day -7 to day - 5), Cy (50 mg kg(-1) i.v. on day -3 and day -2) and E (400 mg m(-2) i.v. on day -5 and day -4). The median age was 43 (range 18-65) years, and 39 patients were male. Diffuse large B-cell lymphoma (40.6%) was the most common histological subtype. All evaluable patients achieved an engraftment of neutrophils (median, day 12) and platelets (median, day 13). Hepatic veno-occlusive disease was observed in four patients (three mild, one moderate grade), and two patients (3.1%) died from treatment-related complications. At a median follow-up of 16.4 months, 15 patients (23.4%) exhibited a relapse or progression, while 13 patients (20.3%) had died of disease. The estimated 3-year overall and progression-free survival for all patients was 72.1 and 70.1%, respectively," wrote J.G. Kim and colleagues, Kyungpook National University, Medical Department.

The researchers concluded: "The conditioning regimen of i.v. Bu/ Cy/E was well tolerated and seemed to be effective in patients with aggressive NHL."

Kim and colleagues published their study in Bone Marrow Transplantation (Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (I.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2007;40(10):919- 924).

For additional information, contact S.K. Sohn, Kyungpook National University, School Medical, Dept. of Hematology Oncology, Kyungpook National University Hospital, 50 Samduck 2-Ga, Taegu 700721, South Korea.

Publisher contact information for the journal Bone Marrow Transplantation is: Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England.

MIB Abstract ID Number: 14342

Proquest Identifier: 1407225061

* To access this Proquest article the user must create an account.

Sun deters cancer risk

Lead Author: [none given]

Townsville Bulletin. Townsville, Qld., 2008-01-05, pg. 18

RECREATIONAL sun exposure could help prevent a type of blood cancer called non-Hodgkin's lymphoma (NHL), a study indicates.

Recreational sun exposure -- defined as hours spent in the sun on non-working days -- between the ages of 18 and 40, reduced the risk of the disease.

Sun exposure could exert its anti-cancer effects by boosting vitamin D production in the skin, the researchers told the International Journal of Cancer.

"If sun exposure does protect against NHL it is an intermittent pattern of sun exposure that is the most protective," Dr Anne Kricker said.

MIB Abstract ID Number: 14345

Proquest Identifier: 1408098911

* To access this Proquest article the user must create an account.

Jefferson to study intravenous Vitamin C vs. cancer

Lead Author: Marie McCullough.

McClatchy - Tribune Business News. Washington: , 2008-01-03

Jan. 3--Thomas Jefferson University researchers are conducting a tiny study that they hope will help answer a big question: Is intravenous Vitamin C effective against cancer?

Beginning next week, they will give high-dose intravenous Vitamin C to 20 non-Hodgkin's lymphoma patients who have failed standard treatments and have a life expectancy of less than a year.

Over 10 weeks, the patients will receive 30 infusions, while the scientists watch for tumor shrinkage or other signs that the progression of the immune-system cancer has slowed or stopped.

"We want to see if there are some trends of hopefulness," physician Daniel Monti, director of Jefferson's Myrna Brind Center of Integrative Medicine, said yesterday.

The theory that Vitamin C can treat cancer was championed decades ago by Linus Pauling, the two-time Nobel laureate-turned-Vitamin C zealot. Pointing to his own inconclusive studies, in which some patients experienced seemingly miraculous cancer cures and remissions, he pushed for more research.

In the 1970s, the federal government finally funded two rigorous clinical trials. But cancer patients showed no benefit, and Pauling's theory was discredited.

The flaw in those studies, Monti and his collaborators now believe, was that the patients took Vitamin C orally.

Only by putting ascorbate directly into a vein can blood levels reach concentrations high enough to be toxic to cancer cells.

Over the last decade, this cancer-cell-killing effect has been clearly shown in lab dishes and in animal studies led by Mark Levine, a nutrition researcher at the National Institutes of Health.

"I am very excited about the study at Thomas Jefferson University," Levine, who is among Monti's collaborators, said in an e-mail.

The Jefferson patients will get infusions of up to 100 grams of Vitamin C -- more than 1,500 oranges' worth.

Levine has shown that at that concentration, ascorbate generates hydrogen peroxide, a powerful oxidant used as a bleaching agent and antiseptic. Although toxic to cancer cells, the chemical does not harm healthy cells.

Jefferson, which is underwriting the study, is among a handful of institutions revisiting the Vitamin C debate.

At the University of Kansas Medical Center, physician Jeanne Drisko recently completed a study of intravenous Vitamin C in 30 ovarian-cancer patients; she expects to publish the results this year.

Drisko hopes these small "stepping-stone" studies will persuade the NIH to fund large, new trials. So far, it has said no, even though Levine's work is respected.

"I think what these initial studies will show us is that it's safe," said Drisko, who consulted on the Jefferson study. "I don't think it will be definitive until we have several large, multicenter trials."

The Jefferson researchers are committed to publishing the results -- no matter what they show.

------

The cancer-cure controversy: Pros, cons and links for the claims about Vitamin C: http://go.philly.com/health

Contact staff writer Marie McCullough at 215-854-2720 or mmccullough@phillynews.com.

MIB Abstract ID Number: 14348

Proquest Identifier: 1406710361

* To access this Proquest article the user must create an account.

Studies from American Cancer Society in the area of cancer described

Lead Author: [none given]

Aging & Elder Health Week, 2008-01-06, EXPANDED REPORTING; Pg. 42

Data detailed in 'Psychological distress of female cancer caregivers: effects of type of cancer and caregivers' spirituality' have been presented. According to recent research from the United States, "This study examined the effects of the survivor's cancer type (gender-specific vs nongender-specific) and the female caregiver's spirituality and caregiving stress on the caregiver's psychological distress. Cancer caregivers, who were nominated by cancer survivors, participated in a nationwide quality-of-life survey with 252 caregivers providing complete data for the variables."

"Breast and ovarian cancer were categorized as gender-specific types of cancer (GTC+), whereas kidney, lung, non-Hodgkin's lymphoma (NHL), and skin melanoma cancers were GTC-. Spirituality, caregiving stress, and psychological distress were measured using the functional assessment of chronic illness therapy--spiritual well-being, stress overload subscale, and profile of mood states--short form, respectively. Hierarchical regression analyses revealed that female caregivers whose care recipient was diagnosed with a nongender specific type of cancer (GTC-group) reported higher psychological distress than did the GTC+ group. The GTC-group also reported lower spirituality and higher caregiving stress related to higher psychological distress than did the GTC+ group. In addition, the beneficial effect of spirituality on reducing psychological distress was more pronounced among the GTC-group or when caregiving stress increased," wrote Y. Kim and colleagues, American Cancer Society.

The researchers concluded: "Our findings suggest that female caregivers of survivors with a nongender-specific cancer may benefit from programs designed to reduce their psychological distress, and caregivers who are low in spirituality need help to derive faith and meaning in the context of cancer care."

Kim and colleagues published their study in Supportive Care In Cancer (Psychological distress of female cancer caregivers: effects of type of cancer and caregivers' spirituality. Supportive Care In Cancer, 2007;15(12):1367-74).

For additional information, contact Y. Kim, Behavioral Research Center, American Cancer Society, Atlanta 30303 USA..

Publisher contact information for the journal Supportive Care In Cancer is: Springer, 233 Spring Street, New York, NY 10013, USA.

MIB Abstract ID Number: 14356

*To access this Lexis-Nexis article the user must create an account.

Research from Tilburg University provide new insights into non-hodgkin lymphoma quality of care

Lead Author: [none given]

Aging & Elder Health Week, 2008-01-06, EXPANDED REPORTING; Pg. 141

Investigators publish new data in the report 'Health-related quality of life and health care utilisation among older long-term cancer survivors: a population-based study.' According to recent research from Netherlands, "The consequences of cancer and its treatment on health-related quality of life (HRQL) and health care utilisation among elderly long-term cancer survivors have rarely been studied. However, the impact can be different for older compared to younger patients due to the higher prevalence of comorbid diseases, a higher risk of treatment-related complications and because they often receive different therapies compared to younger patients."

"Therefore, this study addressed the following questions; do HRQL and health care utilisation differ between younger and elderly cancer survivors, and are those differences age or disease related. A population-based, cross-sectional survey among 1893 long-term survivors of endometrial cancer, prostate cancer and non-Hodgkin's lymphoma was conducted using a cancer registry. HRQL was measured by the SF-36 and health care utilisation was measured with a self-reported questionnaire. Results were compared to a normative population. Patients with disease progression were excluded resulting in a total number of 1112 patients to be analysed. Young non-Hodgkin lymphoma survivors (<70 years) reported lower vitality, bodily pain and general health compared to the normative population while older (70 years) survivors did not differ from the norm. Young lymphoma survivors experienced better physical functioning compared to older survivors. Young endometrial cancer survivors experienced less bodily pain compared to the normative population while older survivors did not differ from the norm. Young endometrial cancer survivors experienced better physical and role functioning compared to older survivors. Young prostate cancer survivors reported less bodily pain compared to the norm while older survivors did not. Young prostate cancer survivors reported higher scores on physical functioning compared to older survivors. Age, comorbid diseases, educational level and current occupation influenced HRQL significantly. Both younger and older cancer survivors visited their medical specialist, but not their GP, significantly more often compared to the age-matched general Dutch population. Both younger and older cancer survivors only sporadically used additional care services after cancer treatment. HRQL of older and younger survivors is comparable, with the exception of physical functioning which is lower in older survivors. This difference in physical functioning was probably not caused by cancer because physical functioning among cancer survivors did not differ much compared to an age-matched normative population," wrote F. Mols and colleagues, Tilburg University.

The researchers concluded: "Both younger and older long-term cancer survivors visited their medical specialist often but only sporadically used additional care services after cancer treatment."

Mols and colleagues published their study in European Journal of Cancer (Health-related quality of life and health care utilisation among older long-term cancer survivors: a population-based study. European Journal of Cancer, 2007;43(15):2211-21).

For additional information, contact F. Mols, Center of Research on Psychology in Somatic Diseases, Tilburg University, PO Box 90153, 5000 LE Tilburg, Netherlands.

Publisher contact information for the European Journal of Cancer is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England.

MIB Abstract ID Number: 14358

*To access this Lexis-Nexis article the user must create an account.

Reports from Xiamen University describe recent advances in lymphoma

Lead Author: [none given]

Biotech Week, 2008-01-09, EXPANDED REPORTING; Pg. 1052

According to recent research from People's Republic of China, "Ig/Ig two-component-determined circulating immune complex (TCIC) may reveal alteration in immune regulation in patients (see also Lymphoma). In the current study, IgM and IgG-TCIC was investigated in sera of patients suffering from esophagus, intestine, lung, nasopharyngeal, ovarian, breast, uterine and thyroid cancers, and hepatocellular carcinoma, Hodgkins lymphoma, non-Hodgkins lymphoma."

"This investigation was performed by detection of IgM/IgG-TCIC and IgG/IgM-TCIC with the use of ELISA by the reciprocal use of coating and detecting antibodies. The current study was carried out in 979 patients with these cancers and 401 healthy controls. We found that down-regulated IgM/IgG-TCIC was a common feature in these patients, whereas levels of IgG/ IgM-TCIC showed significantly higher, lower or no difference with respect to the control. In summary, our results suggest that IgM and IgG-TCIC may play an important role in immune regulation during the course of malignancies and may be a hallmark for cancer pathogenesis. Decreased IgM/IgG-TCIC, accompanied by diverse IgG/IgM-TCIC, forms a peculiar trait in malignancies," wrote T.C. Yang and colleagues, Xiamen University.

The researchers concluded: "Our findings thus provide new insights into immune regulation in patients with malignancies."

Yang and colleagues published their study in International Immunopharmacology (Detection of IgM and IgG complexes provides new insight into immune regulation of patients with malignancies: A randomized controlled trial. International Immunopharmacology, 2007;7(11):1433-1441).

For additional information, contact S.Y. Wang, Xiamen University, School Life Science, Dept. of Biology, Fujian 361005, People's Republic of China.

Publisher contact information for the journal International Immunopharmacology is: Elsevier Science BV,